Evaluation expression of matrix metalloproteinase peripheral profile in multiple sclerosis patients treated with natalizumab

Trial Profile

Evaluation expression of matrix metalloproteinase peripheral profile in multiple sclerosis patients treated with natalizumab

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Jul 2017 New trial record
    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top